Tumor necrosis factor inhibitor-induced psoriasis in a pediatric Crohn's disease patient successfully treated with ustekinumab

Lauren Bonomo, Ellen H. de Moll, Linden Li, Lauren Geller, Michael I. Gordon, David Dunkin

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that these medications can also paradoxically induce a psoriasiform skin reaction in a subset of patients. Goals: We seek to share our experience in treating severe TNF inhibitor-induced psoriasis in a pediatric patient with Crohn's disease. Study: We report a case of a 10-year-old female with Crohn's disease, who developed psoriasis after twelve months of infliximab therapy. Her skin disease was recalcitrant to topical therapies, methotrexate, and phototherapy. Results: The patient was transitioned to ustekinumab with significant improvement in her symptoms and maintenance of remission of her bowel disease. Conclusion: This is the first reported case of a school-age pediatric patient with TNF inhibitor-induced psoriasis treated with ustekinumab. Controlled trials are warranted to fully assess the safety and efficacy of ustekinumab for treating TNF inhibitor-induced psoriasis in the pediatric population.

Original languageEnglish
Pages (from-to)328-331
Number of pages4
JournalJournal of Drugs in Dermatology
Volume19
Issue number3
DOIs
StatePublished - Mar 2020

Fingerprint

Dive into the research topics of 'Tumor necrosis factor inhibitor-induced psoriasis in a pediatric Crohn's disease patient successfully treated with ustekinumab'. Together they form a unique fingerprint.

Cite this